Mohamad A. Hussein

7.1k total citations · 1 hit paper
129 papers, 4.8k citations indexed

About

Mohamad A. Hussein is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Mohamad A. Hussein has authored 129 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Hematology, 71 papers in Molecular Biology and 63 papers in Oncology. Recurrent topics in Mohamad A. Hussein's work include Multiple Myeloma Research and Treatments (95 papers), Protein Degradation and Inhibitors (37 papers) and Cancer Treatment and Pharmacology (31 papers). Mohamad A. Hussein is often cited by papers focused on Multiple Myeloma Research and Treatments (95 papers), Protein Degradation and Inhibitors (37 papers) and Cancer Treatment and Pharmacology (31 papers). Mohamad A. Hussein collaborates with scholars based in United States, United Kingdom and Greece. Mohamad A. Hussein's co-authors include Gordan Srkalović, Rachid Baz, Eric D. Hsi, Bart Barlogie, Jerome B. Zeldis, David Gordon, Anthony Howell, Robert E. Coleman, Lee S. Rosen and John R. Mackey and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Mohamad A. Hussein

127 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

2003 657 citations Mohamad A. Hussein et al. Cancer profile →

Peers

Countries citing papers authored by Mohamad A. Hussein

Since Specialization

Citations

This map shows the geographic impact of Mohamad A. Hussein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamad A. Hussein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamad A. Hussein more than expected).

Fields of papers citing papers by Mohamad A. Hussein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamad A. Hussein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamad A. Hussein. The network helps show where Mohamad A. Hussein may publish in the future.

Co-authorship network of co-authors of Mohamad A. Hussein

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamad A. Hussein. A scholar is included among the top collaborators of Mohamad A. Hussein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamad A. Hussein. Mohamad A. Hussein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials 2018 ·Blood Cancer Journal ·Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K. Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar	59
2	Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma 2012 ·Clinical Lymphoma Myeloma & Leukemia ·Donna M. Weber, Thorsten Graef, Mohamad A. Hussein, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, James S. Hardwick, Sundar Jagannath	37
3	Vorinostat in solid and hematologic malignancies 2009 ·Journal of Hematology & Oncology ·David S. Siegel, Mohamad A. Hussein, Chandra P. Belani, Francisco Robert, Evanthia Galanis, Victoria M. Richon, J. Garcia‐Vargas, César Sanz-Rodrı́guez, Syed Rizvi	151
4	Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen 2008 ·Human Pathology ·Todd W. Kelley, Rachid Baz, Mohamad A. Hussein, Matthew Karafa, James R. Cook	8
5	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma 2008 ·Blood Reviews ·Antonio Palumbo, Meletios Α. Dimopoulos, Jesús F. San Miguel, Jean‐Luc Harousseau, Michel Attal, Mohamad A. Hussein, Stefan Knop, Heinz Ludwig, Marie von Lilienfeld‐Toal, Pieter Sonneveld	30
6	Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 2007 ·Journal of Clinical Oncology ·Ian W. Flinn, Donna Neuberg, Michael R. Grever, Gordon W. Dewald, John M. Bennett, Elisabeth Paietta, Mohamad A. Hussein, Frederick R. Appelbaum, Richard A. Larson, Dennis F. Moore, Martin S. Tallman	300
7	Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma 2007 ·Leukemia & lymphoma ·Rachid Baz, Suzanne Fanning, Lori Kunkel, Sameh Gaballa, Mary Ann Karam, Janice Reed, Megan Kelly, Mohamad A. Hussein	11
8	Immunomodulatory Analogues of Thalidomide in the Treatment of Multiple Myeloma 2006 ·Clinical Lymphoma & Myeloma ·(unknown), (unknown), Mohamad A. Hussein	11
9	Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma 2006 ·Cancer ·Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher, Mohamad A. Hussein	101
10	The Emerging Role of Arsenic Trioxide as an Immunomodulatory Agent in the Management of Multiple Myeloma 2006 ·Acta Haematologica ·Sujith Kalmadi, Mohamad A. Hussein	16
11	Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma 2006 ·Mayo Clinic Proceedings ·Mohamad A. Hussein, Rachid Baz, Gordan Srkalović, (unknown), (unknown), Eric D. Hsi, Steven Andrèsen, Mary Ann Karam, Janice Reed, Beth Faiman, Megan Kelly, Esteban Walker	84
12	Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis 2005 ·PubMed ·Gordan Srkalović, Marte Grønlie Cameron, Steven R. Deitcher, (unknown), Mohamad A. Hussein	14
13	Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias 2004 ·Cancer ·Rachid Baz, Carlos Alemany, Ralph Green, Mohamad A. Hussein	25
14	Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer 2004 ·Investigational New Drugs ·Navneet S. Majhail, Mohamad A. Hussein, Thomas Olencki, G. Thomas Budd, Laura S. Wood, Paul Elson, Ronald M. Bukowski	6
15	Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease 2004 ·Cancer ·Gordan Srkalović, Marte Grønlie Cameron, Lisa Rybicki, Steven R. Deitcher, (unknown), Mohamad A. Hussein	140
16	New treatment strategies for multiple myeloma 2004 ·Seminars in Hematology ·Mohamad A. Hussein	6
17	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia 2003 ·British Journal of Haematology ·Eric D. Hsi, Kenneth J. Kopecky, Frederick R. Appelbaum, David H. Boldt, Tom Frey, Margaret Loftus, Mohamad A. Hussein	36
18	Use of Melphalan, Thalidomide, and Dexamethasone in Treatment of Refractory and Relapsed Multiple Myeloma 2002 ·Medical Oncology ·Gordan Srkalović, Paul Elson, (unknown), Mary Ann Karam, Mohamad A. Hussein	38
19	Multiple myeloma: present and future 2002 ·Current Opinion in Oncology ·Mohamad A. Hussein, (unknown), Isador H. Lieberman	35
20	Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. 2000 ·PubMed ·Mohamad A. Hussein	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact